169 related articles for article (PubMed ID: 36596981)
21. Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas.
do Canto AM; da Silva Marcelino BMR; Schussel JL; Wastner BF; Sassi LM; Corrêa L; de Freitas RR; Hasséus B; Kjeller G; Junior CAL; Braz-Silva PH
Clin Oral Investig; 2019 Feb; 23(2):779-784. PubMed ID: 29855709
[TBL] [Abstract][Full Text] [Related]
22. Radical vs conservative treatment of intraosseous ameloblastoma: Systematic review and meta-analysis.
Hendra FN; Natsir Kalla DS; Van Cann EM; de Vet HCW; Helder MN; Forouzanfar T
Oral Dis; 2019 Oct; 25(7):1683-1696. PubMed ID: 30548549
[TBL] [Abstract][Full Text] [Related]
23. Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation.
Fernandes GS; Girardi DM; Bernardes JPG; Fonseca FP; Fregnani ER
BMC Cancer; 2018 Sep; 18(1):887. PubMed ID: 30208863
[TBL] [Abstract][Full Text] [Related]
24. Factors affecting the accuracy of anti-BRAF V600E immunohistochemistry results in ameloblastomas.
Chang JYF; Lu PH; Tseng CH; Wang YP; Lee JJ; Chiang CP
J Oral Pathol Med; 2023 Apr; 52(4):342-350. PubMed ID: 36625499
[TBL] [Abstract][Full Text] [Related]
25. Ameloblastoma: biological profile of 3677 cases.
Reichart PA; Philipsen HP; Sonner S
Eur J Cancer B Oral Oncol; 1995 Mar; 31B(2):86-99. PubMed ID: 7633291
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic accuracy of immunohistochemistry compared with molecular tests for detection of BRAF V600E mutation in ameloblastomas: Systematic review and meta-analysis.
Martins-de-Barros AV; Anjos RSD; Silva CCG; Silva EDOE; Araújo FADC; Carvalho MV
J Oral Pathol Med; 2022 Mar; 51(3):223-230. PubMed ID: 35090195
[TBL] [Abstract][Full Text] [Related]
27. Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: Systematic review.
González-González R; López-Verdín S; Lavalle-Carrasco J; Molina-Frechero N; Isiordia-Espinoza M; Carreón-Burciaga RG; Bologna-Molina R
World J Clin Oncol; 2020 Jan; 11(1):31-42. PubMed ID: 31976308
[TBL] [Abstract][Full Text] [Related]
28. BRAF p.V600E status in epithelial areas of ameloblastoma with different histological aspects: Implications to the clinical practice.
Sant'Ana MSP; Dos Santos Costa SF; da Silva MP; Martins-Chaves RR; Pereira TDSF; de Oliveira EM; Martínez Pedraza R; de Castro WH; Gomes CC; Gomez RS; Fonseca FP
J Oral Pathol Med; 2021 May; 50(5):478-484. PubMed ID: 33377543
[TBL] [Abstract][Full Text] [Related]
29. Correlation of BRAF mutational status with clinical characteristics and survival outcomes of patients with ameloblastoma: the experience of 11 Italian centres.
Bonacina R; Indini A; Massazza G; Rulli E; Gianatti A; Mandalà M;
J Clin Pathol; 2022 Aug; 75(8):555-559. PubMed ID: 33827932
[TBL] [Abstract][Full Text] [Related]
30. Progress towards personalized medicine for ameloblastoma.
Gomes CC; Diniz MG; Gomez RS
J Pathol; 2014 Apr; 232(5):488-91. PubMed ID: 24749150
[TBL] [Abstract][Full Text] [Related]
31. High frequency of BRAF V600E mutation in Iranian population ameloblastomas.
Derakhshan S; Aminishakib P; Karimi A; Saffar H; Abdollahi A; Mohammadpour H; Kharazi Fard MJ; Memarha A
Med Oral Patol Oral Cir Bucal; 2020 Jul; 25(4):e502-e507. PubMed ID: 32388526
[TBL] [Abstract][Full Text] [Related]
32. BRAF p.V600E Mutational Status Does Not Correlate with Biological Behavior in Conventional Ameloblastomas: A Disease-Free Survival Analysis.
Martins-de-Barros AV; da Costa Araújo FA; Faro TF; de Aquino AAT; Barbosa Neto AG; da Silva HAM; de Lima ELS; Muniz MTC; de Oliveira E Silva ED; de Vasconcelos Carvalho M
Head Neck Pathol; 2024 Mar; 18(1):23. PubMed ID: 38504068
[TBL] [Abstract][Full Text] [Related]
33. BRAF-V600E expression correlates with ameloblastoma aggressiveness.
Fregnani ER; Perez DE; Paes de Almeida O; Fonseca FP; Soares FA; Castro-Junior G; Alves FA
Histopathology; 2017 Feb; 70(3):473-484. PubMed ID: 27681305
[TBL] [Abstract][Full Text] [Related]
34. High prevalence of BRAF V600E mutations in Korean patients with ameloblastoma: Clinicopathological significance and correlation with epithelial-mesenchymal transition.
Oh KY; Cho SD; Yoon HJ; Lee JI; Ahn SH; Hong SD
J Oral Pathol Med; 2019 May; 48(5):413-420. PubMed ID: 30889301
[TBL] [Abstract][Full Text] [Related]
35. Bcl-2 is a prognostic marker and its silencing inhibits recurrence in ameloblastomas.
Kim JY; Kim J; Bazarsad S; Cha IH; Cho SW; Kim J
Oral Dis; 2019 May; 25(4):1158-1168. PubMed ID: 30801855
[TBL] [Abstract][Full Text] [Related]
36. BRAF V600E expression in ameloblastomas-A 36-patient cohort from Helsinki University Hospital.
Kelppe J; Thorén H; Ristimäki A; Haglund C; Sorsa T; Hagström J
Oral Dis; 2019 May; 25(4):1169-1174. PubMed ID: 30811720
[TBL] [Abstract][Full Text] [Related]
37. The BRAF p.V600E mutation is a common event in ameloblastomas but is absent in odontogenic keratocysts.
Zhang R; Yang Q; Qu J; Hong Y; Liu P; Li T
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Mar; 129(3):229-235. PubMed ID: 31987674
[TBL] [Abstract][Full Text] [Related]
38. Adenoid Ameloblastoma with BRAF p.V600E Mutation Revealing Ameloblastomatous Origin: A First Case Report.
Noda Y; Sawada S; Sakagami T; Kojima Y; Higasa K; Tsuta K
Head Neck Pathol; 2023 Sep; 17(3):788-792. PubMed ID: 37093491
[TBL] [Abstract][Full Text] [Related]
39. The landscape of genetic alterations in ameloblastomas relates to clinical features.
Gültekin SE; Aziz R; Heydt C; Sengüven B; Zöller J; Safi AF; Kreppel M; Buettner R
Virchows Arch; 2018 May; 472(5):807-814. PubMed ID: 29388014
[TBL] [Abstract][Full Text] [Related]
40. It was not possible to detect BRAF V600E mutation in circulating cell-free DNA from patients with ameloblastoma: A diagnostic accuracy study.
Martins-de-Barros AV; da Costa Araújo FA; Barros AMI; Dos Santos EGF; Barbosa Neto AG; da Silva HAM; de Lima ELS; Muniz MTC; Neves RFSN; de Hollanda Valente RO; de Oliveira E Silva ED; de Vasconcelos Carvalho M
J Oral Pathol Med; 2024 Apr; 53(4):258-265. PubMed ID: 38494749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
